{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:45:54Z","timestamp":1789886754929,"version":"4.0.1"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Inflammatory bowel diseases (IBD), including Crohn\u2019s disease and ulcerative colitis, are persistent, relapsing immune mediated disorders of the gastrointestinal tract associated with significant morbidity and considerable health-care costs. Current therapeutic strategies, such as corticosteroids, immunomodulators, and biologic agents including anti-tumour necrosis factor (anti-TNF) therapies, provide a clinical advantage; however, there is a 30\u201340% primary non-response rate followed by a 50% secondary non-response rate. This highlights the need for novel therapeutic targets that can specifically address patient heterogeneity. Type I interferons (IFN-Is) are broad acting cytokines that apply state-dependent effects on epithelial intestinal homeostasis. At normal biological levels, IFN-Is reinforce epithelial barrier integrity by regulating tight junction formation, epithelial turnover, and antiviral defence mechanisms. However, in IBD, dysregulated IFN-I signalling facilitates atypical immune cell recruitment, epithelial apoptosis, and prolonged epithelial cell inflammation. The impact of IFN-Is on the dysregulation of the epithelial barrier in IBD remains poorly understood. Patient-derived intestinal organoids represent a physiologically relevant model that aids in the understanding of IFN-I signalling pathways in epithelial cells, allowing for adequate studies on the epithelial\u2013immune crosstalk phenomenon in IBD. This review identifies and highlights IFN-Is as a promising but context-dependent therapeutic target. Interpreting the molecular mechanisms of IFN-Is and their role on the intestinal epithelial barrier function will benefit our understanding of treatment responsiveness as well as aid in resolving current therapeutic challenges in IBD.<\/jats:p>","DOI":"10.3389\/fmed.2025.1713424","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:26:59Z","timestamp":1764052019000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Type I interferons in inflammatory bowel diseases: balancing barrier integrity, repair and inflammation in the intestinal epithelium"],"prefix":"10.3389","volume":"12","author":[{"given":"Mikayla R.","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roslyn A.","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safina","family":"Gadeock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e41120","DOI":"10.7759\/cureus.41120","article-title":"Advancements in inflammatory bowel disease: a narrative review of diagnostics, management, epidemiology, prevalence, patient outcomes, quality of life, and clinical presentation","volume":"15","author":"Muzammil","year":"2023","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.2147\/JIR.S268262","article-title":"Indeterminate colitis - update on treatment options","volume":"14","author":"Venkateswaran","year":"2021","journal-title":"J Inflamm Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1053\/j.sempedsurg.2017.10.003","article-title":"Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes","volume":"26","author":"Yu","year":"2017","journal-title":"Semin Pediatr Surg"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1136\/gutjnl-2019-320022","article-title":"25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future","volume":"70","author":"D'Haens","year":"2021","journal-title":"Gut"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.25122\/jml-2018-0075","article-title":"A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease","volume":"12","author":"Seyedian","year":"2019","journal-title":"J Med Life"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e001225","DOI":"10.1136\/bmjgast-2023-001225","article-title":"Biological therapy for inflammatory bowel disease: cyclical rather than lifelong treatment?","volume":"11","author":"Selinger","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40259-013-0045-2","article-title":"Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents","volume":"27","author":"Kemp","year":"2013","journal-title":"BioDrugs"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"5389","DOI":"10.2147\/JIR.S470520","article-title":"Restore intestinal barrier integrity: An approach for inflammatory bowel disease therapy","volume":"17","author":"Kong","year":"2024","journal-title":"J Inflamm Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/bmb\/ldab001","article-title":"An update on the role of anti-IL-12\/IL23 agents in the management of inflammatory bowel disease","volume":"138","author":"Nigam","year":"2021","journal-title":"Br Med Bull"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/med.21601","article-title":"The role of integrins in the pathogenesis of inflammatory bowel disease: approved and investigational anti-integrin therapies","volume":"40","author":"Dotan","year":"2020","journal-title":"Med Res Rev"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","article-title":"JAK inhibitors for inflammatory bowel disease: recent advances","volume":"15","author":"Honap","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"9300","DOI":"10.3748\/wjg.v22.i42.9300","article-title":"Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases","volume":"22","author":"Billmeier","year":"2016","journal-title":"World J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.20524\/aog.2024.0894","article-title":"The national burden of inflammatory bowel disease in the United States from 1990-2019: results from the global burden of disease study database","volume":"37","author":"Alsakarneh","year":"2024","journal-title":"Ann Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000492615","article-title":"Annual incidence and phenotypic presentation of IBD in southern New Zealand: an 18-year epidemiological analysis","volume":"3","author":"Coppell","year":"2018","journal-title":"Inflamm Intest Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"103329","DOI":"10.1016\/j.ebiom.2021.103329","article-title":"Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: current and novel biomarkers","volume":"66","author":"Cui","year":"2021","journal-title":"EBioMedicine"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00535-015-1098-4","article-title":"Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease","volume":"51","author":"Okamoto","year":"2016","journal-title":"J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nri3608","article-title":"Intestinal epithelial cells: regulators of barrier function and immune homeostasis","volume":"14","author":"Peterson","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"686","DOI":"10.17235\/reed.2015.3846\/2015","article-title":"The intestinal barrier function and its involvement in digestive disease","volume":"107","author":"Salvo Romero","year":"2015","journal-title":"Rev Esp Enferm Dig"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ani12020145","article-title":"Integrity of the intestinal barrier: the involvement of epithelial cells and microbiota-a mutual relationship","volume":"12","author":"Gierynska","year":"2022","journal-title":"Animals"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"715611","DOI":"10.3389\/fphys.2021.715611","article-title":"Role of barrier integrity and dysfunctions in maintaining the healthy gut and their health outcomes","volume":"12","author":"Panwar","year":"2021","journal-title":"Front Physiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jcmgh.2017.03.007","article-title":"Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease","volume":"4","author":"Martini","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrm3721","article-title":"Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration","volume":"15","author":"Barker","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41575-023-00766-3","article-title":"Paracellular permeability and tight junction regulation in gut health and disease","volume":"20","author":"Horowitz","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jcmgh.2021.02.007","article-title":"Regulation of intestinal barrier function by microbial metabolites","volume":"11","author":"Ghosh","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e2350631","DOI":"10.1002\/eji.202350631","article-title":"Epithelial-immune cell crosstalk for intestinal barrier homeostasis","volume":"54","author":"Yao","year":"2024","journal-title":"Eur J Immunol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"848344","DOI":"10.3389\/fmed.2022.848344","article-title":"The role and function of mucins and its relationship to inflammatory bowel disease","volume":"9","author":"Kang","year":"2022","journal-title":"Front Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/nu15102275","article-title":"Gut microbial metabolite butyrate and its therapeutic role in inflammatory bowel disease: a literature review","volume":"15","author":"Recharla","year":"2023","journal-title":"Nutrients"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"669913","DOI":"10.3389\/fmed.2021.669913","article-title":"Rules of engagement: epithelial-microbe interactions and inflammatory bowel disease","volume":"8","author":"Jergens","year":"2021","journal-title":"Front Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2019.06.029","article-title":"Intra- and inter-cellular rewiring of the human Colon during ulcerative colitis","volume":"178","author":"Smillie","year":"2019","journal-title":"Cell"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1093\/ibd\/izaa089","article-title":"Inflammatory bowel disease through the Lens of single-cell RNA-seq technologies","volume":"26","author":"Corridoni","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.cell.2019.08.008","article-title":"Single-cell analysis of Crohn's disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy","volume":"178","author":"Martin","year":"2019","journal-title":"Cell"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"103331","DOI":"10.1016\/j.autrev.2023.103331","article-title":"Cytokines and intestinal epithelial permeability: a systematic review","volume":"22","author":"Meyer","year":"2023","journal-title":"Autoimmun Rev"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.4049\/jimmunol.178.7.4641","article-title":"IL-1beta causes an increase in intestinal epithelial tight junction permeability","volume":"178","author":"Al-Sadi","year":"2007","journal-title":"J Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e13357","DOI":"10.1111\/asj.13357","article-title":"Regulation of the intestinal barrier by nutrients: the role of tight junctions","volume":"91","author":"Suzuki","year":"2020","journal-title":"Anim Sci J"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.20524\/aog.2020.0457","article-title":"Inflammatory bowel disease pathobiology: the role of the interferon signature","volume":"33","author":"Andreou","year":"2020","journal-title":"Ann Gastroenterol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1007\/s00018-017-2520-2","article-title":"Advances in anti-viral immune defence: revealing the importance of the IFN JAK\/STAT pathway","volume":"74","author":"Raftery","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.immuni.2006.08.007","article-title":"Type I interferons in host defense","volume":"25","author":"Stetson","year":"2006","journal-title":"Immunity"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1136\/gut.2005.090134","article-title":"Interfering with interferons in inflammatory bowel disease","volume":"55","author":"Ghosh","year":"2006","journal-title":"Gut"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1053\/j.gastro.2019.07.031","article-title":"Interferon lambda promotes Paneth cell death via STAT1 signaling in mice and is increased in inflamed Ileal tissues of patients with Crohn's disease","volume":"157","author":"Gunther","year":"2019","journal-title":"Gastroenterology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/imm.13954","article-title":"IFN-lambda: unleashing its potential in disease therapies from acute inflammation regulation to cancer immunotherapy","volume":"176","author":"Tang","year":"2025","journal-title":"Immunology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"102412","DOI":"10.1016\/j.coi.2024.102412","article-title":"Role of type-I and type-III interferons in gastrointestinal homeostasis and pathogenesis","volume":"86","author":"Wright","year":"2024","journal-title":"Curr Opin Immunol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"7533","DOI":"10.1016\/j.cell.2024.10.010","article-title":"Type III interferons induce pyroptosis in gut epithelial cells and impair mucosal repair","volume":"187","author":"Jena","year":"2024","journal-title":"Cell"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.immuni.2012.07.001","article-title":"Maintaining poise: commensal microbiota calibrate interferon responses","volume":"37","author":"McAleer","year":"2012","journal-title":"Immunity"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1002\/eji.201344401","article-title":"Type I interferons have opposing effects during the emergence and recovery phases of colitis","volume":"44","author":"Rauch","year":"2014","journal-title":"Eur J Immunol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.clinre.2012.12.004","article-title":"Efficacy and safety of interferon-gamma-targeted therapy in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Cui","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1038\/s41467-021-22928-0","article-title":"Critical role of interferons in gastrointestinal injury repair","volume":"12","author":"McElrath","year":"2021","journal-title":"Nat Commun"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1186\/ar2912","article-title":"Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment","volume":"12","author":"van Baarsen","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/ibd\/izaa216","article-title":"Type I and II interferon signatures can predict the response to anti-TNF agents in inflammatory bowel disease patients: involvement of the microbiota","volume":"26","author":"Mavragani","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1136\/gut.2010.226860","article-title":"Suppression of inflammation in ulcerative colitis by interferon-beta-1a is accompanied by inhibition of IL-13 production","volume":"60","author":"Mannon","year":"2011","journal-title":"Gut"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1046\/j.1365-2036.2002.01264.x","article-title":"Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial","volume":"16","author":"Musch","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/gut.52.9.1286","article-title":"Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study","volume":"52","author":"Nikolaus","year":"2003","journal-title":"Gut"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1542-3565(05)00208-9","article-title":"Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial","volume":"3","author":"Musch","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1111\/j.1572-0241.2001.03875.x","article-title":"An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis","volume":"96","author":"Madsen","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1136\/gut.52.12.1728","article-title":"A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis","volume":"52","author":"Tilg","year":"2003","journal-title":"Gut"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-230X-9-22","article-title":"Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study","volume":"9","author":"Pena Rossi","year":"2009","journal-title":"BMC Gastroenterol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/BF02064982","article-title":"Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease","volume":"40","author":"Gasche","year":"1995","journal-title":"Dig Dis Sci"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41586-019-0992-y","article-title":"Colonic epithelial cell diversity in health and inflammatory bowel disease","volume":"567","author":"Parikh","year":"2019","journal-title":"Nature"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071775","article-title":"Butyrate and the intestinal epithelium: modulation of proliferation and inflammation in homeostasis and disease","volume":"10","author":"Salvi","year":"2021","journal-title":"Cells"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/mi.2008.62","article-title":"Guanylate-binding protein-1 is expressed at tight junctions of intestinal epithelial cells in response to interferon-gamma and regulates barrier function through effects on apoptosis","volume":"2","author":"Schnoor","year":"2009","journal-title":"Mucosal Immunol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1084\/jem.20182031","article-title":"Interferon-induced guanylate-binding proteins: guardians of host defense in health and disease","volume":"216","author":"Tretina","year":"2019","journal-title":"J Exp Med"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1136\/gutjnl-2013-305863","article-title":"Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration","volume":"63","author":"Tschurtschenthaler","year":"2014","journal-title":"Gut"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1128\/MCB.00988-15","article-title":"Type I interferons control proliferation and function of the intestinal epithelium","volume":"36","author":"Katlinskaya","year":"2016","journal-title":"Mol Cell Biol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00603-20","article-title":"Selective interferon responses of intestinal epithelial cells minimize tumor necrosis factor alpha cytotoxicity","volume":"94","author":"Van Winkle","year":"2020","journal-title":"J Virol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fbioe.2018.00197","article-title":"Mimicking epithelial tissues in three-dimensional cell culture models","volume":"6","author":"Torras","year":"2018","journal-title":"Front Bioeng Biotechnol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"e1407","DOI":"10.1002\/cti2.1407","article-title":"An autologous colonic organoid-derived monolayer model to study immune: bacterial interactions in Crohn's disease patients","volume":"11","author":"Angus","year":"2022","journal-title":"Clin Transl Immunology"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/nm.2470","article-title":"Isolation and in vitro expansion of human colonic stem cells","volume":"17","author":"Jung","year":"2011","journal-title":"Nat Med"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/ibd\/izac212","article-title":"Molecular and functional characterization of human intestinal organoids and monolayers for modeling epithelial barrier","volume":"29","author":"Jelinsky","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41420-023-01556-1","article-title":"Stem cell-derived intestinal organoids: a novel modality for IBD","volume":"9","author":"Tian","year":"2023","journal-title":"Cell Death Discov"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13104-022-05925-4","article-title":"Assessment of source material for human intestinal organoid culture for research and clinical use","volume":"15","author":"Urbano","year":"2022","journal-title":"BMC Res Notes"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3389\/fmed.2019.00334","article-title":"Intestinal organoids as a tool for inflammatory bowel disease research","volume":"6","author":"Angus","year":"2019","journal-title":"Front Med"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00109-021-02043-9","article-title":"Gastrointestinal epithelial innate immunity-regionalization and organoids as new model","volume":"99","author":"Kayisoglu","year":"2021","journal-title":"J Mol Med (Berl)"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1043.3","DOI":"10.1096\/fasebj.31.1_supplement.1043.3","article-title":"An inherent defect in tight junction structure and permeability is apparent in colonoids from Crohn\u2019s disease patients","author":"Gadeock","year":"2017","journal-title":"The FASEB J"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1049.6","DOI":"10.1096\/fasebj.31.1_supplement.1049.6","article-title":"The differential response of human epithelial derived colonic organoids to TLR agonists","volume":"31","author":"Samuel","year":"2017","journal-title":"FASEB J"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature09691","article-title":"Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro","volume":"470","author":"Spence","year":"2011","journal-title":"Nature"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.stem.2016.11.001","article-title":"Induced quiescence of Lgr5+ stem cells in intestinal organoids enables differentiation of hormone-producing Enteroendocrine cells","volume":"20","author":"Basak","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"110118","DOI":"10.1016\/j.isci.2024.110118","article-title":"Organoids as regenerative medicine for inflammatory bowel disease","volume":"27","author":"Hammerhoj","year":"2024","journal-title":"iScience"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12195","article-title":"The role of type I interferons in intestinal infection, homeostasis, and inflammation","volume":"260","author":"Cho","year":"2014","journal-title":"Immunol Rev"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"102413","DOI":"10.1016\/j.coi.2024.102413","article-title":"Structure-function of type I and III interferons","volume":"86","author":"de Weerd","year":"2024","journal-title":"Curr Opin Immunol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"7186","DOI":"10.4049\/jimmunol.0903116","article-title":"Commensal Escherichia coli reduces epithelial apoptosis through IFN-alphaA-mediated induction of guanylate binding protein-1 in human and murine models of developing intestine","volume":"184","author":"Mirpuri","year":"2010","journal-title":"J Immunol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1172\/JCI22996","article-title":"Toll-like receptor 9-induced type I IFN protects mice from experimental colitis","volume":"115","author":"Katakura","year":"2005","journal-title":"J Clin Invest"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"G439","DOI":"10.1152\/ajpgi.00104.2022","article-title":"DNA sensor-associated type I interferon signaling is increased in ulcerative colitis and induces JAK-dependent inflammatory cell death in colonic organoids","volume":"323","author":"Flood","year":"2022","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"416","DOI":"10.4049\/immunohorizons.2200025","article-title":"Transcriptional and cytotoxic responses of human intestinal organoids to IFN types I, II, and III","volume":"6","author":"Constant","year":"2022","journal-title":"Immunohorizons"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/gut.2003.036632","article-title":"Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment","volume":"53","author":"Zeissig","year":"2004","journal-title":"Gut"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"S-1353","DOI":"10.1016\/S0016-5085(24)03558-3","article-title":"Type I interferon targets as predictors of clinical non-response to anti-TNFs in IBD patients and their regulation of epithelial repair responses","volume":"166","author":"Gadeock","year":"2024","journal-title":"Gastroenterology"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41540-022-00224-x","article-title":"Mapping the epithelial-immune cell interactome upon infection in the gut and the upper airways","volume":"8","author":"Poletti","year":"2022","journal-title":"NPJ Syst Biol Appl"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.4049\/jimmunol.1301093","article-title":"Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis","volume":"191","author":"Kole","year":"2013","journal-title":"J Immunol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1713424\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:27:06Z","timestamp":1764052026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1713424\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":87,"alternative-id":["10.3389\/fmed.2025.1713424"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1713424","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"article-number":"1713424"}}